MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. (NYSE American: MAIA) is a clinical-stage biopharmaceutical company developing targeted cancer immunotherapies, led by ateganosine (THIO), an investigational telomere-targeting drug candidate designed to promote cancer-cell death and immune response. Its lead program evaluates ateganosine,… From the company’s description.
In fiscal 2025, MAIA Biotechnology, Inc. reported a net loss of $22.40M. Operations used $18.84M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What MAIA Biotechnology, Inc. does
In the company’s own words
MAIA Biotechnology, Inc. (NYSE American: MAIA) is a clinical-stage biopharmaceutical company developing targeted cancer immunotherapies, led by ateganosine (THIO), an investigational telomere-targeting drug candidate designed to promote cancer-cell death and immune response. Its lead program evaluates ateganosine, generally followed by an immune checkpoint inhibitor, in advanced non-small cell lung cancer (NSCLC); the company is also developing trials in hepatocellular, colorectal and small cell lung cancers. Its THIO-101 Phase 2 study evaluates ateganosine in NSCLC, while the Phase 3 THIO-104 trial compares the treatment sequence with chemotherapy in third-line patients resistant to checkpoint inhibitors and chemotherapy. MAIA is also researching second-generation telomere-targeting compounds, including seven candidates undergoing further evaluation, and maintains global development and commercial rights to ateganosine. The company conducts clinical and research activities through wholly owned subsidiaries in Australia and Romania; it reports no operating segments. MAIA was incorporated in 2018 and began its first ateganosine Phase 2 trial in 2022. Its website is www.MAIABiotech.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CHICAGO, IL
- Fiscal year end
- December
- CIK
- 1878313
- SIC
- 2834
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns MAIA Biotechnology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · MAIA Biotechnology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do MAIA Biotechnology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of MAIA Biotechnology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in MAIA Biotechnology, Inc.'s last four quarterly filings that the numbers alone won't show?”